| scholarly article | Q13442814 |
| P50 | author | Adam J. Olszewski | Q43234155 |
| P2093 | author name string | Susan K Boolbol | |
| Paula Klein | |||
| Theresa Shao | |||
| William Sikov | |||
| Kwadwo Boachie-Adjei | |||
| Yazan Migdady | |||
| Bachir J Sakr | |||
| P2860 | cites work | Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome | Q42468745 |
| Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma | Q42504088 | ||
| Molecular stratification of triple-negative breast cancers | Q42783792 | ||
| Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
| T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy | Q43294040 | ||
| Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less | Q44178084 | ||
| Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. | Q44268615 | ||
| Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. | Q46911956 | ||
| Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller | Q47404684 | ||
| Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas | Q48111542 | ||
| Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. | Q54535173 | ||
| Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes | Q56779241 | ||
| Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy | Q56928413 | ||
| Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer | Q57578316 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Matching methods for causal inference: A review and a look forward | Q28749221 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 | ||
| Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes | Q32034551 | ||
| Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less | Q33718750 | ||
| Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype | Q33922150 | ||
| Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. | Q34514319 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status | Q35583711 | ||
| Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria | Q35677457 | ||
| Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples | Q36319710 | ||
| Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature | Q36464108 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer | Q36955125 | ||
| Choice and interpretation of statistical tests used when competing risks are present | Q37124914 | ||
| Constructing inverse probability weights for marginal structural models | Q37321459 | ||
| Are propensity scores really superior to standard multivariable analysis? | Q37880361 | ||
| Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer | Q38495651 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| Breast cancer subtypes and the risk of local and regional relapse. | Q42468027 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 215-223 | |
| P577 | publication date | 2013-01-26 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. | |
| P478 | volume | 138 |
| Q92067860 | Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis |
| Q40900023 | Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients |
| Q36145737 | Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer |
| Q35716564 | Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population |
| Q38253815 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. |
| Q55094642 | The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. |
| Q51673307 | The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. |
Search more.